Published in TB and Outbreaks Week, December 21st, 2004
Financial details were not disclosed.
Earlier this year Crucell and IAVI entered into an exclusive license agreement to develop an AIDS vaccine based on Crucell's AdVac technology.
The AdVac vectors, adenovirus serotypes 11 and 35, have shown promising results as vectors for AIDS vaccines in a series of studies by Crucell in collaboration with Harvard Medical School.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week